BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 34484872)

  • 1. Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants.
    Pipperger L; Riepler L; Kimpel J; Siller A; Stoitzner P; Bánki Z; von Laer D
    Oncoimmunology; 2021; 10(1):1959140. PubMed ID: 34484872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
    Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
    Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
    Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
    Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
    Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Consequences of in vitro Infection of Human Peripheral Blood Leukocytes with Vesicular Stomatitis Virus.
    Tomczyk T; Wróbel G; Chaber R; Siemieniec I; Piasecki E; Krzystek-Korpacka M; Orzechowska BU
    J Innate Immun; 2018; 10(2):131-144. PubMed ID: 29306950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
    Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
    J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
    Zhang P; Han X; Tan W; Chen D; Sun Q
    Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.
    Porosnicu M; Quinson AM; Crossley K; Luecke S; Lauer UM
    Future Oncol; 2022 Aug; 18(24):2627-2638. PubMed ID: 35699077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
    Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
    Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
    Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
    Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP.
    Vijver SV; Danklmaier S; Pipperger L; Gronauer R; Floriani G; Hackl H; Das K; Wollmann G
    Front Immunol; 2022; 13():1100730. PubMed ID: 36741416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
    Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
    J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Porcine monocyte-derived dendritic cells can be differentially activated by vesicular stomatitis virus and its matrix protein mutants.
    Sun G; Fang X; Wu H; Zhou X; Ke Y; Sun T
    Vet Microbiol; 2018 Jun; 219():30-39. PubMed ID: 29778202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.
    Muik A; Stubbert LJ; Jahedi RZ; Geiβ Y; Kimpel J; Dold C; Tober R; Volk A; Klein S; Dietrich U; Yadollahi B; Falls T; Miletic H; Stojdl D; Bell JC; von Laer D
    Cancer Res; 2014 Jul; 74(13):3567-78. PubMed ID: 24812275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
    Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
    Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
    Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
    Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
    Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
    Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.